Epstein, Richard A <br/><br/>
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.  [electronic resource] 

 -  Yale journal of health policy, law, and ethics  2005 
 - 741-70 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1535-3532 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-Inflammatory Agents, Non-Steroidal--therapeutic use<br/>Celecoxib<br/>Chromans--therapeutic use<br/>Clinical Trials as Topic<br/>Cyclooxygenase Inhibitors--therapeutic use<br/>Drug Industry--legislation & jurisprudence<br/>Drug and Narcotic Control--legislation & jurisprudence<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Isoxazoles--therapeutic use<br/>Lactones--therapeutic use<br/>Myocardial Infarction--chemically induced<br/>Paternalism<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Pyrazoles--therapeutic use<br/>Sulfonamides--therapeutic use<br/>Sulfones--therapeutic use<br/>Thiazolidinediones--therapeutic use<br/>Troglitazone<br/>Truth Disclosure<br/>United States<br/>United States Food and Drug Administration--legislation & jurisprudence<br/>Vasodilator Agents--therapeutic use